Nautilus Q3 net loss widens to $14.5M; OpEx up 262%; cash at $374M

Nautilus Biotechnology, Inc.

2021-Q3 EPS reported -$0.47

Net loss of $14.5M for Q3 2021 vs. $4.0M loss in Q3 2020.
Operating expenses $14.6M, up 262% YoY on higher headcount and public-company costs.
Cash, cash equivalents and investments totaled $374.0M at September 30, 2021.
Strategic partnership with Abcam and two new research collaborations (pharma and MD Anderson).
Published theoretical foundation for PrISM single-molecule protein identification method.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.